Renate A Richardus1, C Ruth Butlin2, Khorshed Alam2, Kallyan Kundu2, Annemieke Geluk3, Jan Hendrik Richardus4. 1. Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. 2. Rural Health Program, The Leprosy Mission International Bangladesh, Nilphamari, Bangladesh. 3. Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. 4. Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. Electronic address: j.richardus@erasmusmc.nl.
Abstract
BACKGROUND: Although BCG is used as a vaccine against tuberculosis, it also protects against leprosy. Previous evaluation over 18 years of an intervention of two doses BCG for 3536 household contacts of leprosy patients showed that 28 (23%) out of 122 contacts diagnosed with leprosy, developed symptoms 2-10 months after vaccination. This study describes contacts of leprosy patients in Bangladesh who developed leprosy within 12 weeks after receiving a single BCG dose. METHODS: A cluster RCT in Bangladesh aims to study the effectiveness of the BCG vaccine versus BCG in combination with single dose rifampicin (SDR) given 2 to 3 months after BCG, in the prevention of leprosy among contacts of newly diagnosed leprosy patients. During the first 1,5 years of this ongoing trial we identified contacts who developed leprosy within the first 12 weeks after receiving BCG vaccination, the timeframe before SDR is given. RESULTS: We identified 21 contacts who developed leprosy within 12 weeks after BCG vaccination among 5196 vaccinated contacts (0.40%). All 21 cases presented with paucibacillary (PB) leprosy, including children and adults. About half of these cases had previously received BCG vaccination as indicated by the presence of a BCG scar; 43% presented with signs of nerve function impairment and/or Type 1 (reversal) reaction, and 56% of the index patients had multibacillary (MB) leprosy. CONCLUSION: An unexpectedly high proportion of healthy contacts of leprosy patients presented with PB leprosy within 12 weeks after receiving BCG vaccination, possibly as a result of boosted cell-mediated immunity by homologues of Mycobacterium leprae antigens in BCG. Various immunological mechanisms could underlie this phenomenon, including an immune reconstitution inflammatory syndrome (IRIS). Further studies are required to determine whether BCG vaccination merely altered the incubation period or actually changed the course of the infection from self-limiting, subclinical infection to manifest disease.
BACKGROUND: Although BCG is used as a vaccine against tuberculosis, it also protects against leprosy. Previous evaluation over 18 years of an intervention of two doses BCG for 3536 household contacts of leprosypatients showed that 28 (23%) out of 122 contacts diagnosed with leprosy, developed symptoms 2-10 months after vaccination. This study describes contacts of leprosypatients in Bangladesh who developed leprosy within 12 weeks after receiving a single BCG dose. METHODS: A cluster RCT in Bangladesh aims to study the effectiveness of the BCG vaccine versus BCG in combination with single dose rifampicin (SDR) given 2 to 3 months after BCG, in the prevention of leprosy among contacts of newly diagnosed leprosypatients. During the first 1,5 years of this ongoing trial we identified contacts who developed leprosy within the first 12 weeks after receiving BCG vaccination, the timeframe before SDR is given. RESULTS: We identified 21 contacts who developed leprosy within 12 weeks after BCG vaccination among 5196 vaccinated contacts (0.40%). All 21 cases presented with paucibacillary (PB) leprosy, including children and adults. About half of these cases had previously received BCG vaccination as indicated by the presence of a BCG scar; 43% presented with signs of nerve function impairment and/or Type 1 (reversal) reaction, and 56% of the index patients had multibacillary (MB) leprosy. CONCLUSION: An unexpectedly high proportion of healthy contacts of leprosypatients presented with PB leprosy within 12 weeks after receiving BCG vaccination, possibly as a result of boosted cell-mediated immunity by homologues of Mycobacterium leprae antigens in BCG. Various immunological mechanisms could underlie this phenomenon, including an immune reconstitution inflammatory syndrome (IRIS). Further studies are required to determine whether BCG vaccination merely altered the incubation period or actually changed the course of the infection from self-limiting, subclinical infection to manifest disease.
Authors: Renate Richardus; Anouk van Hooij; Susan J F van den Eeden; Louis Wilson; Korshed Alam; Jan Hendrik Richardus; Annemieke Geluk Journal: Front Immunol Date: 2018-04-04 Impact factor: 7.561
Authors: Daiane Santos Dos Santos; Nádia Cristina Duppre; Euzenir Nunes Sarno; Roberta Olmo Pinheiro; Anna Maria Sales; José Augusto Da Costa Nery; Milton Ozório Moraes; Luiz Antônio Bastos Camacho Journal: Trials Date: 2018-04-23 Impact factor: 2.279
Authors: Mariateresa Coppola; Susan J F van den Eeden; Naoko Robbins; Louis Wilson; Kees L M C Franken; Linda B Adams; Tom P Gillis; Tom H M Ottenhoff; Annemieke Geluk Journal: Front Immunol Date: 2018-02-26 Impact factor: 7.561
Authors: Anastasia Polycarpou; Martin J Holland; Ioannis Karageorgiou; Ayad Eddaoudi; Stephen L Walker; Sam Willcocks; Diana N J Lockwood Journal: Front Cell Infect Microbiol Date: 2016-07-08 Impact factor: 5.293
Authors: Anouk van Hooij; Elisa M Tjon Kon Fat; Renate Richardus; Susan J F van den Eeden; Louis Wilson; Claudia J de Dood; Roel Faber; Korshed Alam; Jan Hendrik Richardus; Paul L A M Corstjens; Annemieke Geluk Journal: Sci Rep Date: 2016-09-29 Impact factor: 4.379
Authors: Malcolm S Duthie; Maria T Pena; Gigi J Ebenezer; Thomas P Gillis; Rahul Sharma; Kelly Cunningham; Michael Polydefkis; Yumi Maeda; Masahiko Makino; Richard W Truman; Steven G Reed Journal: NPJ Vaccines Date: 2018-03-28 Impact factor: 7.344
Authors: Ana Paula Vieira; Maria Angela Bianconcini Trindade; Flávio Jota de Paula; Neusa Yurico Sakai-Valente; Alberto José da Silva Duarte; Francine Brambate Carvalhinho Lemos; Gil Benard Journal: BMC Infect Dis Date: 2017-04-24 Impact factor: 3.090
Authors: Maria Tió-Coma; Anouk van Hooij; Kidist Bobosha; Jolien J van der Ploeg-van Schip; Sayera Banu; Saraswoti Khadge; Pratibha Thapa; Chhatra B Kunwar; Isabela M Goulart; Yonas Bekele; Deanna A Hagge; Milton O Moraes; Rosane M B Teles; Roberta Olmo Pinheiro; Erik W van Zwet; Jelle J Goeman; Abraham Aseffa; Mariëlle C Haks; Tom H M Ottenhoff; Robert L Modlin; Annemieke Geluk Journal: Sci Rep Date: 2019-11-29 Impact factor: 4.379